News

Transplants from any donor, without toxicity?

Pre-treatment with an antibody-drug combination avoids side effects in mice; could substitute for current toxic regimens using chemotherapy or radiation

Multi-center study led by Dana-Farber/Boston Children's contributes to FDA approval of a new treatment for acute lymphoblastic leukemia

Multi-center study led by Dana-Farber/Boston Children's contributes to FDA approval of a new treatment for acute lymphoblastic leukemia

Boston Children’s Hospital to receive $1.5M to initiate basic work to expand gene therapy treatment of sickle cell disease into developing countries

The research will focus on adapting gene therapy for use in low-resource areas with high rates of the disease.

CRISPR-Cas9 screen opens new targets for Ewing sarcoma, other childhood cancers

In this Vector report, research finds that drugs targeting the TP53 pathway can curb tumor cell proliferation in Ewing sarcoma.

New gene therapy strategy for sickle cell disease shows early promise in humans

A patient with a severe form of sickle cell disease is symptom-free after gene therapy knocks down BCL11A and restores fetal hemoglobin production.

Fishing for new leads in rare mucosal melanoma

Vector reports that zebrafish are helping scientists dissect intricate molecular pathways in cancer and discover new treatment approaches.

Dana-Farber and Boston Children’s Hospital teams win Moonshot grants

The federal Beau Biden Cancer Moonshot program has awarded two grants of $2.5 million over five years to two research teams led by scientists from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

In zebrafish, a way to find new cancer therapies, targeting tumor promoters

Vector reports on a new study that finds that retinoic acid, best known as an acne treatment, may also be effective in treating adenoid cystic carcinoma.

Leslie Kean, MD, PhD, joins Dana-Farber/Boston Children's Stem Cell Transplantation program

Kean will assume overall leadership in the program’s clinical practice and research in coordination with the Clinical Director, Leslie Lehmann, MD.

Dana-Farber/Boston Children's again ranked among the top national pediatric cancer programs

U.S. News & World Report has ranked Dana-Farber/Boston Children's Cancer and Blood Disorders Center the top pediatric cancer program in New England and #3 in the nation in its new 2018-19 Best Children's Hospitals report.